Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-... Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Mehr anzeigen
BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics...
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder...
The efficacy and safety of CAPLYTA (lumateperone) as a maintenance treatment in adults with schizophrenia was demonstrated in a randomized withdrawal trial The study demonstrated a statistically...
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA’s strong prescription uptake continues: Q3 2024...
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 4.01 | 4.8653239505 | 82.42 | 86.86 | 81.9 | 472786 | 84.82307166 | CS |
| 4 | 9.51 | 12.3634945398 | 76.92 | 93.45 | 75.57 | 753110 | 86.33748043 | CS |
| 12 | 12.405 | 16.757852077 | 74.025 | 93.45 | 70.9 | 564769 | 79.89037607 | CS |
| 26 | 20.76 | 31.612608497 | 65.67 | 93.45 | 64.72 | 801687 | 75.07611846 | CS |
| 52 | 27.54 | 46.7651553744 | 58.89 | 93.45 | 58.14 | 853269 | 71.9071173 | CS |
| 156 | 42.93 | 98.6896551724 | 43.5 | 93.45 | 34.43 | 832176 | 59.53345967 | CS |
| 260 | 77.17 | 833.369330454 | 9.26 | 93.45 | 9.23 | 932318 | 45.06138546 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
